|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
19 February 2015 |
|
Main ID: |
NCT00024453 |
|
Date of registration:
|
13/09/2001 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Teicoplanin in Treating Septicemia in Patients Who Are Receiving Chemotherapy Through a Central Venous Catheter
|
|
Scientific title:
|
The Use of Teicoplanin in the Treatment of Septicaemia Caused by Coagulase-Negative Staphylococci - A Randomized Study Comparing Bolus Injection With Infused and/or Line-Locked Teicoplanin |
|
Date of first enrolment:
|
February 1999 |
|
Target sample size:
|
1360 |
|
Recruitment status: |
Active, not recruiting |
|
URL:
|
http://clinicaltrials.gov/show/NCT00024453 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Primary Purpose: Supportive Care
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
Ireland
|
United Kingdom
| | | | | | |
|
Contacts
|
|
Name:
|
Barry Pizer, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Royal Liverpool Children's Hospital, Alder Hey |
| | |
|
Key inclusion & exclusion criteria
|
DISEASE CHARACTERISTICS:
- Suspected septicemia caused by coagulase-negative staphylococci
- Single or double lumen (no triple lumen) central venous catheter (CVC) (including
subcutaneous ports) that can be flushed and aspirated
- Expected to remain in situ for at least 8 weeks
- No coagulase-negative septicemia associated with existing CVC within the past 12
weeks
- Receiving chemotherapy for neoplastic condition, aplastic anemia, Fanconi's anemia,
Langerhans' cell histiocytosis, or myelodysplasia
PATIENT CHARACTERISTICS:
Age:
- 2 months and over
Performance status:
- Not specified
Life expectancy:
- Not specified
Hematopoietic:
- Not specified
Hepatic:
- Not specified
Renal:
- Creatinine clearance at least 60 mL/min
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- See Disease Characteristics
Endocrine therapy
- Not specified
Radiotherapy
- Not specified
Surgery
- Not specified
Age minimum:
N/A
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Infection
|
|
Intervention(s)
|
|
Biological: teicoplanin
|
|
Secondary ID(s)
|
|
EU-20124
|
|
CCLG-SC-1999-01
|
|
CDR0000068944
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|